Professor Dominique Bremond-Gignac is the Head of Ophthalmology at University Hospital Necker-Enfants Malades of Paris Cité University in Paris, France. In this interview, we chatted with her about her experiences of combination treatment; in particular, with prescribing HOYA MiYOSMART spectacle lenses and atropine for children with myopia.
The LAMP2 study explored the efficacy of low-concentration atropine to delay the onset of myopia in at-risk children. The results found there was no significant difference between 0.01% atropine and the placebo, but 0.05% atropine was able to reduce myopia incidence and speed of myopic progression for pre-myopes.
A mixed-race cohort of Australian children demonstrated that atropine 0.01% was safe and well tolerated, although myopia control effects were only found in those of European or other/mixed ancestry. Those of East Asian or South Asian ethnicity showed no benefit. Overall results were impacted by high drop-out in the control group in the second year of the study.
We asked some key atropine questions of myopia thought leader Professor Mark Bullimore, who has published numerous landmark papers in the field, including his newest on the inconsistencies found in compounded atropine. Learn about the present and the future of atropine treatment for childhood myopia.
We had the privilege of chatting with Professor Karla Zadnik who is Principal Investigator of the CHAMP study on low-concentration atropine. Learn about how this study is a unique and important addition to our understanding of topical atropine in myopia control.
Low dose atropine is a popular off-label choice for myopia control, and typically needs to be compounded. The results of this survey show there are varying methods for producing, storing and labelling low concentration, compounded atropine in the Unites States. This could influence the safety and efficacy of these atropine formulations for myopia control.
This prospective observational study found that DIMS spectacle lenses, atropine 0.01% and the combination of the two all showed robust efficacy for myopia control in European children. The combination treatment showed slightly better refractive control than the mono-therapies, but axial length growth was similar in all treatment groups.
Spectacle lenses for myopia control provide a clear central zone and a ‘treatment’ area for myopic defocus. This study found that atropine 0.01% and glare situations had minimal impacts on visual performance when adults wore the DIMS spectacle lens. This indicates likely tolerance of the combination in children.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
Orthokeratology is effective for myopia control but is it suitable for a child with trichiasis and corneal staining? This case compiles the treatment suggestions for managing a young myopic patient with trichiasis from the Facebook community, with a focus on safety.
